Princeton, N.J. – – September 15, 2026 -- CytoSorbents Corporation (NASDAQ: CTSO) will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York City from September 14–16, 2026, as the blood-purification device maker seeks to update investors on its regulatory pipeline and path to profitability.
CEO and CFO to join fireside chat on September 14
Dr. Phillip Chan, Chief Executive Officer, and Peter Mariani, Chief Financial Officer, will join Sean Lee, Vice President of Equity Research at H.C. Wainwright, for a fireside chat at 11:30 a.m. EDT at the Lotte New York Palace Hotel. The two executives will also hold scheduled one-on-one meetings with investors during the three-day event. A webcast replay will remain archived for up to 90 days on the company's investor relations site.
CytoSorb device has logged 300,000 cumulative uses across 70 countries
CytoSorbents' lead product, CytoSorb, holds EU approval and is distributed in more than 70 countries, with cumulative use exceeding 300,000 devices. The polymer-bead cartridge technology is designed to remove toxins, blood thinners and inflammatory agents from blood during dialysis, ECMO and cardiac surgery procedures. CytoSorb has FDA Emergency Use Authorization for adult COVID-19 patients in respiratory failure but remains unapproved for broader use in the United States.
DrugSorb-ATR carries two FDA Breakthrough Device Designations
The company's investigational DrugSorb-ATR antithrombotic removal system has received Breakthrough Device Designations from the FDA for removing the blood thinner ticagrelor and for removing the direct oral anticoagulants apixaban and rivaroxaban during urgent cardiothoracic surgery. CytoSorbents is pursuing FDA approval for the device and plans to seek Health Canada clearance once U.S. regulatory visibility improves. DrugSorb-ATR has not yet been cleared in either market.
Company targets cash-flow break-even in the second half of 2026
CytoSorbents disclosed it is restructuring its direct sales team and strategy in Germany as part of broader cost-reduction efforts. Management has set a target of reaching cash-flow break-even in the second half of 2026, a goal the company flagged as subject to financing risk and regulatory outcomes in its most recent SEC filings.